Identification of BRAF p. V600E-Mutant and Wild-Type by MR Imaging in Pleomorphic Xanthoastrocytoma and Anaplastic Pleomorphic Xanthoastrocytoma

References

1. 1.↵
   1. Rao AA,
   2. Laack NN,
   3. Giannini C, et al

   . Pleomorphic xanthoastrocytoma in children and adolescents. Pediatr Blood Cancer 2010;55:290–94 doi:10.1002/pbc.22490 pmid:20582976

   CrossRefPubMed
2. 2.↵
   1. Kepes JJ,
   2. Rubinstein LJ,
   3. Eng LF

   . Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis—a study of 12 cases. Cancer 1979;44:1839–52

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Kleihues P,
   2. Burger PC,
   3. Scheithauer BW

   . The new WHO classification of brain tumors. Brain Pathol 1993;3:255–68 doi:10.1111/j.1750-3639.1993.tb00752.x pmid:8293185

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Louis DN,
   2. Ohgaki H,
   3. Wiestler OD, et al

   . The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007;114:97–109 doi:10.1007/s00401-007-0243-4 pmid:17618441

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Ida CM,
   2. Rodriguez FJ,
   3. Burger PC, et al

   . Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 2015;25:575–86 doi:10.1111/bpa.12217 pmid:25318587

   CrossRefPubMed
6. 6.↵
   1. Hirose T,
   2. Ishizawa K,
   3. Sugiyama K, et al

   . Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types. Histopathology 2008;52:183–93 doi:10.1111/j.1365-2559.2007.02926.x pmid:18184267

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Giannini C,
   2. Scheithauer BW,
   3. Burger PC, et al

   . Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 1999;85:2033–45

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Louis DN,
   2. Perry A,
   3. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
9. 9.↵
   1. Wesseling P,
   2. Capper D

   . WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 2018;44:139–50 doi:10.1111/nan.12432 pmid:28815663

   CrossRefPubMed
10. 10.↵
    1. Marton E,
    2. Feletti A,
    3. Orvieto E, et al

    . Malignant progression inpleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurol Sci 2007;252:144–53 doi:10.1016/j.jns.2006.11.008 pmid:17189643

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Rutkowski MJ,
    2. Oh T,
    3. Niflioglu GG, et al

    . Pleomorphic xanthoastrocytoma with anaplastic features: retrospective case series. World Neurosurg 2016;95:368–74 doi:10.1016/j.wneu.2016.07.068 pmid:27476694

    CrossRefPubMed
12. 12.↵
    1. Ma C,
    2. Feng R,
    3. Chen H, et al

    . BRAF V600E, TERT, and IDH2 mutations in pleomorphic xanthoastrocytoma: observations from a large case-series study. World Neurosurg 2018;120:e1225–33 doi:10.1016/j.wneu.2018.09.050 pmid:30240866

    CrossRefPubMed
13. 13.↵
    1. Dias-Santagata D,
    2. Lam Q,
    3. Vernovsky K, et al

    . BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011;6:e17948 doi:10.1371/journal.pone.0017948 pmid:21479234

    CrossRefPubMed
14. 14.↵
    1. Tatevossian RG,
    2. Lawson AR,
    3. Forshew T, et al

    . MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010;222:509–14 doi:10.1002/jcp.21978 pmid:19937730

    CrossRefPubMed
15. 15.↵
    1. Jacob K,
    2. Quang-Khuong DA,
    3. Jones DT, et al

    . Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011;17:4650–60 doi:10.1158/1078-0432.CCR-11-0127 pmid:21610151

    Abstract/FREE Full Text
16. 16.↵
    1. Maurer G,
    2. Tarkowski B,
    3. Baccarini M

    . Raf kinases in cancer: roles and therapeutic opportunities. Oncogene 2011;30:3477–88 doi:10.1038/onc.2011.160 pmid:21577205

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Schindler G,
    2. Capper D,
    3. Meyer J, et al

    . Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405 doi:10.1007/s00401-011-0802-6 pmid:21274720

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Chamberlain MC

    . Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol 2013;114:237– 40 doi:10.1007/s11060-013-1176-5 pmid:23756728

    CrossRefPubMed
19. 19.↵
    1. Tabouret E,
    2. Bequet C,
    3. Denicolaï E, et al

    . BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Eur J Surg Oncol 2015;41:1685–90 doi:10.1016/j.ejso.2015.09.012 pmid:26454767

    CrossRefPubMed
20. 20.↵
    1. Vuong HG,
    2. Altibi AM,
    3. Duong UN, et al

    . BRAF mutation is associated with an improved survival in glioma-a systematic review and meta-analysis. Mol Neurobiol 2018;55:3718–24 doi:10.1007/s12035-017-0599-y pmid:28534272

    CrossRefPubMed
21. 21.↵
    1. Tonse R,
    2. Gupta T,
    3. Epari S, et al

    . Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. J Neurooncol 2018;136:343–50 doi:10.1007/s11060-017-2658-7 pmid:29147864

    CrossRefPubMed
22. 22.↵
    1. Brown NF,
    2. Carter T,
    3. Kitchen N, et al

    . Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol 2017;6:291–96 doi:10.2217/cns-2017-0006 pmid:28984141

    CrossRefPubMed
23. 23.↵
    1. She D,
    2. Liu J,
    3. Xing Z, et al

    . MR imaging features of anaplastic pleomorphic xanthoastrocytoma mimicking high-grade astrocytoma. AJNR Am J Neuroradiol 2018;39:1446–52 doi:10.3174/ajnr.A5701 pmid:29903923

    Abstract/FREE Full Text
24. 24.↵
    1. Louis DN,
    2. Wesseling P,
    3. Aldape K, et al

    . cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 2020;30:844–56 doi:10.1111/bpa.12832 pmid:32307792

    CrossRefPubMed
25. 25.↵
    1. Gimi B,
    2. Cederberg K,
    3. Derinkuyu B, et al

    . Utility of apparent diffusion coefficient ratios in distinguishing common pediatric cerebellar tumors. Acad Radiol 2012;19:794–800 doi:10.1016/j.acra.2012.03.004 pmid:22513110

    CrossRefPubMed
26. 26.↵
    1. Mukherjee P,
    2. Miller JH,
    3. Shimony JS, et al

    . Normal brain maturation during childhood: developmental trends characterized with diffusion-tensor MR imaging. Radiology 2001;221:349–58 doi:10.1148/radiol.2212001702 pmid:11687675

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Perkins SM,
    2. Mitra N,
    3. Fei W, et al

    . Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis. J Neurooncol 2012;110:99–104 doi:10.1007/s11060-012-0939-8 pmid:22843450

    CrossRefPubMed
28. 28.↵
    1. Yan J,
    2. Cheng J,
    3. Liu F, et al

    . Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes. Sci Rep 2018;8:14275 doi:10.1038/s41598-018-32273-w pmid:30250216

    CrossRefPubMed
29. 29.↵
    1. Yang RR,
    2. Aibaidula A,
    3. Wang WW, et al

    . Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathol 2018;136:641–55 doi:10.1007/s00401-018-1874-3 pmid:29948154

    CrossRefPubMed
30. 30.↵
    1. Lindsay AJ,
    2. Rush SZ,
    3. Fenton LZ

    . Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status. J Neurooncol 2014;118:395–404 doi:10.1007/s11060-014-1450-1 pmid:24792487

    CrossRefPubMed
31. 31.↵
    1. Ostrom QT,
    2. Gittleman H,
    3. Liao P, et al

    . CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 2017;19:v1–88 doi:10.1093/neuonc/nox158 pmid:29117289

    CrossRefPubMed
32. 32.↵
    1. Thakkar JP,
    2. Dolecek TA,
    3. Horbinski C, et al

    . Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 2014;23:1985–96 doi:10.1158/1055-9965.EPI-14-0275 pmid:25053711

    Abstract/FREE Full Text
33. 33.↵
    1. Rasmussen BK,
    2. Hansen S,
    3. Laursen RJ, et al

    . Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the Danish Neuro-Oncology Registry. J Neurooncol 2017;135:571–79 doi:10.1007/s11060-017-2607-5 pmid:28861666

    CrossRefPubMed
34. 34.↵
    1. Yu S,
    2. He L,
    3. Zhuang X, et al

    . Pleomorphic xanthoastrocytoma: MR imaging findings in 19 patients. Acta Radiol 2011;52:223–28 doi:10.1258/ar.2010.100221 pmid:21498352

    CrossRefPubMed
35. 35.↵
    1. Crespo-Rodriguez AM,
    2. Smirniotopoulos JG,
    3. Rushing EJ

    . MR and CT imaging of 24 pleomorphic xanthoastrocytomas (PXA) and a review of the literature. Neuroradiology 2007;49:307–15 doi:10.1007/s00234-006-0191-z pmid:17205313

    CrossRefPubMed
36. 36.↵
    1. Purkait S,
    2. Bansal S,
    3. Malgulwar PB

    . BRAF V600E-mutated central nervous system tumor with divergent morphological feature: anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like. Neuropathology 2019;39:64–67 doi:10.1111/neup.12527 pmid:30557911

    CrossRefPubMed
37. 37.↵
    1. Moore W,
    2. Mathis D,
    3. Gargan L, et al

    . Pleomorphic xanthoastrocytoma of childhood: MR imaging and diffusion MR imaging features. AJNR Am J Neuroradiol 2014;35:2192–96 doi:10.3174/ajnr.A4011 pmid:24994821

    Abstract/FREE Full Text